These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

605 related articles for article (PubMed ID: 24142549)

  • 1. MSN anti-cancer nanomedicines: chemotherapy enhancement, overcoming of drug resistance, and metastasis inhibition.
    He Q; Shi J
    Adv Mater; 2014 Jan; 26(3):391-411. PubMed ID: 24142549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in mesoporous silica-based nanocarriers for co-delivery and combination therapy against cancer.
    Castillo RR; Colilla M; Vallet-Regí M
    Expert Opin Drug Deliv; 2017 Feb; 14(2):229-243. PubMed ID: 27402029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Engineering Nanomedicines to Overcome Multidrug Resistance in Cancer Therapy.
    Beretta GL; Cavalieri F
    Curr Med Chem; 2016; 23(1):3-22. PubMed ID: 26438248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overcoming multidrug resistance of cancer cells by direct intranuclear drug delivery using TAT-conjugated mesoporous silica nanoparticles.
    Pan L; Liu J; He Q; Wang L; Shi J
    Biomaterials; 2013 Apr; 34(11):2719-30. PubMed ID: 23337327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug Resistance in Metastatic Breast Cancer: Tumor Targeted Nanomedicine to the Rescue.
    Gote V; Nookala AR; Bolla PK; Pal D
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Codelivery of anticancer drugs and siRNA by mesoporous silica nanoparticles.
    Hanafi-Bojd MY; Ansari L; Malaekeh-Nikouei B
    Ther Deliv; 2016 Sep; 7(9):649-55. PubMed ID: 27582236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nanomedicines as emerging platform for simultaneous delivery of cancer therapeutics: new developments in overcoming drug resistance and optimizing anticancer efficacy.
    Hussain Z; Arooj M; Malik A; Hussain F; Safdar H; Khan S; Sohail M; Pandey M; Choudhury H; Ei Thu H
    Artif Cells Nanomed Biotechnol; 2018; 46(sup2):1015-1024. PubMed ID: 29873531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-Analysis of Efficacy of Chemotherapy Delivered by Mesoporous Silica Nanoparticles to Tumor-Bearing Mice.
    McGoron A
    Crit Rev Biomed Eng; 2020; 48(6):327-418. PubMed ID: 33641279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual targeting mesoporous silica nanoparticles for inhibiting tumour cell invasion and metastasis.
    Li W; Guo Z; Zheng K; Ma K; Cui C; Wang L; Yuan Y; Tang Y
    Int J Pharm; 2017 Dec; 534(1-2):71-80. PubMed ID: 28958879
    [TBL] [Abstract][Full Text] [Related]  

  • 14. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
    Mao C; Li F; Zhao Y; Debinski W; Ming X
    Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in Functionalized Mesoporous Silica Nanoparticles for Tumor Targeted Drug Delivery and Theranostics.
    Zhang W; Liu M; Liu A; Zhai G
    Curr Pharm Des; 2017; 23(23):3367-3382. PubMed ID: 27784244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanomedicine therapeutic approaches to overcome cancer drug resistance.
    Markman JL; Rekechenetskiy A; Holler E; Ljubimova JY
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1866-79. PubMed ID: 24120656
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A targeted nanoplatform co-delivering chemotherapeutic and antiangiogenic drugs as a tool to reverse multidrug resistance in breast cancer.
    Tian F; Dahmani FZ; Qiao J; Ni J; Xiong H; Liu T; Zhou J; Yao J
    Acta Biomater; 2018 Jul; 75():398-412. PubMed ID: 29874597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multifunctional mesoporous silica nanoplatform based on silicon nanoparticles for targeted two-photon-excited fluorescence imaging-guided chemo/photodynamic synergetic therapy in vitro.
    Li S; Zhang Y; He XW; Li WY; Zhang YK
    Talanta; 2020 Mar; 209():120552. PubMed ID: 31892096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance.
    Tekchandani P; Kurmi BD; Paliwal SR
    Mini Rev Med Chem; 2017; 17(18):1793-1810. PubMed ID: 26891930
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pH-responsive mesoporous silica nanoparticles-based multi-drug delivery system for overcoming multi-drug resistance.
    He Q; Gao Y; Zhang L; Zhang Z; Gao F; Ji X; Li Y; Shi J
    Biomaterials; 2011 Oct; 32(30):7711-20. PubMed ID: 21816467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.